Narcolepsy - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 43 pages report, published by Global Markets Direct

Keywords : Narcolepsy Therapeutic Products under Development, Key Players in Narcolepsy Therapeutics, Narcolepsy Pipeline Overview, Narcolepsy Pipeline, Narcolepsy Pipeline Assessment

Report ThumbnailSeptember-2013
Narcolepsy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Narcolepsy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Narcolepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Narcolepsy. Narcolepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Narcolepsy.
- A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Narcolepsy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Narcolepsy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Narcolepsy, H2 2013 7
  • Products under Development for Narcolepsy - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Narcolepsy, H2 2013 7
  • Products under Development for Narcolepsy - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 10
  • Number of Products under Investigation by Universities/Institutes, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • Athersys, Inc., H2 2013 16
  • Evotec Aktiengesellschaft, H2 2013 17
  • Jazz Pharmaceuticals, Inc., H2 2013 18
  • Ferrer Internacional S.A., H2 2013 19
  • Concert Pharmaceuticals, Inc., H2 2013 20
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Narcolepsy Therapeutics - Drug Profile Updates 34
  • Narcolepsy Therapeutics - Discontinued Products 35
  • Narcolepsy Therapeutics - Dormant Products 36
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Narcolepsy Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Narcolepsy 7
  • Narcolepsy Therapeutics under Development by Companies 9
  • Narcolepsy Therapeutics under Investigation by Universities/Institutes 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Narcolepsy Therapeutics - Products under Development by Companies 14
  • Narcolepsy Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Narcolepsy Therapeutics Development 16
  • Athersys, Inc. 16
  • Evotec Aktiengesellschaft 17
  • Jazz Pharmaceuticals, Inc. 18
  • Ferrer Internacional S.A. 19
  • Concert Pharmaceuticals, Inc. 20
  • Narcolepsy - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • Histamine H3 Receptor Antagonists - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • EVT-501 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • SKL-N05 - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • C-10291 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • deuterium-modified sodium oxybate - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • Orexin Receptor Agonist Program - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Benztropine Analogs - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Narcolepsy Therapeutics - Drug Profile Updates 34
  • Narcolepsy Therapeutics - Discontinued Products 35
  • Narcolepsy Therapeutics - Dormant Products 36
  • Narcolepsy - Product Development Milestones 37
  • Featured News & Press Releases 37
  • Jun 03, 2013: Aerial BioPharma Announces Presentation Of ADX-NO5 Results At SLEEP 2013 Meeting 37
  • Dec 17, 2012: FDA Announces Combined Use Of Jazz Pharma's Xyrem With Alcohol Or CNS Depressants May Lead To Respiratory Depression 37
  • Dec 04, 2012: Jazz Pharma Obtains Additional Xyrem Patent From USPTO 38
  • Sep 11, 2012: Jazz Pharma Announces Issuance Of New Formulation Patent For Xyrem 38
  • Aug 29, 2012: Aerial BioPharma Receives FDA Orphan Drug Designation For Narcolepsy Drug In Development 38
  • Aug 10, 2012: Mylan Launches Generic Provigil Tablets 39
  • Jun 08, 2012: Mylan Settles Provigil Litigation With Teva 39
  • Apr 30, 2012: Teva Settles Nuvigil Litigation With Mylan 40
  • Apr 18, 2012: Teva To Present New Data On NUVIGIL At 2012 American Academy Of Neurology Annual Meeting 40
  • Apr 05, 2012: Mylan Sues FDA Seeking Ruling That Teva Holds No Exclusivity For Generic Version Of Provigil 40
  • Appendix 42
  • Methodology 42
  • Coverage 42
  • Secondary Research 42
  • Primary Research 42
  • Expert Panel Validation 42
  • Contact Us 43
  • Disclaimer 43

Please select a license type

Share

Related Products

Global Markets DirectNarcolepsy - Pipeline Review, H2 2013Product ThumbnailNarcolepsy - Pipeline Review, H2 2013, Industry ReportProduct #: 113354
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved